摘要
背景:骨肉瘤(OS)是一种以年轻人为主的肿瘤性疾病,它通常发生在骨生长的区域,肿瘤细胞在晚期呼吸衰竭时转移到肺部。硒。这种疾病没有真正的治疗方法,常规药物会产生副作用,从而降低患者的生活质量。需要新的、更安全的药物,一种途径是使用纳豆。能够阻碍肿瘤生长的铝化合物。 目的:对磷虾油和鱼油这两种生物实体进行评价。在长达72h的时间过程中,将人OS细胞暴露于磷虾油、鱼油、EPA和DHA中。 结果:磷虾油在24、48和72h分别抑制了23、50和64%的细胞增殖,而鱼油在24、48和72小时内无显著变化。 泰雷西汀Gly、EPA和DHA促进了该肿瘤细胞的增殖和迁移。磷虾油对OS的抑制作用与临床常用药物阿霉素0.5和1μ相似。 结论:磷虾油可与标准的临床应用相结合,控制原发性肿瘤的生长,更重要的是控制肿瘤的转移。
关键词: 癌症,DHA,EPA,鱼油,磷虾油,骨肉瘤。
图形摘要
Current Drug Targets
Title:The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration
Volume: 19 Issue: 5
关键词: 癌症,DHA,EPA,鱼油,磷虾油,骨肉瘤。
摘要: Background: Osteosarcoma (OS) is a neoplastic condition afflicting mostly the young, as the lesion usually occurs in areas of bone growth with tumour cells metastasising to the lungs in advanced disease. There is no real cure for the disease, with conventional drugs causing side-effects that decrease the quality of life of sufferers. Newer and safer drugs are needed, and one avenue is to use natural compounds that can stunt the growth of the tumour.
Objective: In this study, two such biological entities were evaluated: krill oil and fish oil. Human OS cells were exposed to krill oil, fish oil, EPA and DHA in time-course assays lasting up to 72h.
Results: Krill oil inhibited 23, 50 and 64% of cell proliferation at 24, 48 and 72h respectively, while fish oil resulted in no significant changes although an increase was observed at 24h. Interestingly EPA and DHA promoted OS cell proliferation and migration in this neoplasia. The inhibitory effect of krill oil was comparable to 0.5 and 1µM doxorubicin, a commonly used clinical drug for OS treatment.
Conclusion: These results indicate that krill oil may be used in combination with standard clinical practices to control primary tumour growth, and more importantly, metastasis.
Export Options
About this article
Cite this article as:
The Effect of Krill Oil and n-3 Polyunsaturated Fatty Acids on Human Osteosarcoma Cell Proliferation and Migration, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1389450116666150107152206
DOI https://dx.doi.org/10.2174/1389450116666150107152206 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis
Current Pharmaceutical Design Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Vitamin D and Physical Performance in Athletes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets RECKing MMP: Relevance of Reversion-inducing Cysteine-rich Protein with Kazal Motifs as a Prognostic Marker and Therapeutic Target for Cancer (A Review)
Anti-Cancer Agents in Medicinal Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Small Molecule Protein-Protein Inhibitors for the p53-MDM2 Interaction
Current Topics in Medicinal Chemistry Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Inorganic Phosphate as a Signaling Molecule: A Potential Strategy in Osteosarcoma Treatment
Current Pharmaceutical Design In Vitro Inhibitory Effect of Recombinant Human Calprotectin on Nalm6 Leukemia Cell Line
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Liposheres as a Novel Carrier for Lipid Based Drug Delivery: Current and Future Directions
Recent Patents on Drug Delivery & Formulation Role of CGRP-Receptor Component Protein (RCP) in CLR/RAMP Function
Current Protein & Peptide Science Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Compartmentalized Platforms for Neuro-Pharmacological Research
Current Neuropharmacology Extracellular Ca<sup>2+</sup> Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Current Cancer Drug Targets Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design